Boosted classification trees result in minor to modest improvement in the accuracy in classifying cardiovascular outcomes compared to conventional classification trees.
暂无分享,去创建一个
[1] K. Swedberg,et al. Gender does not affect postdischarge outcomes in patients hospitalized for worsening heart failure with reduced ejection fraction (from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan [EVEREST] Trial). , 2012, The American journal of cardiology.
[2] V. Roger,et al. Comorbidity and Ventricular and Vascular Structure and Function in Heart Failure With Preserved Ejection Fraction: A Community-Based Study , 2012, Circulation. Heart failure.
[3] D. J. Veldhuisen,et al. Comparing New Onset Heart Failure with Reduced Ejection Fraction and New Onset Heart Failure with Preserved Ejection Fraction: An Epidemiologic Perspective , 2012, Current Heart Failure Reports.
[4] R. McKelvie,et al. Sex Differences in Clinical Characteristics and Outcomes in Elderly Patients With Heart Failure and Preserved Ejection Fraction: The Irbesartan in Heart Failure With Preserved Ejection Fraction (I-PRESERVE) Trial , 2012, Circulation. Heart failure.
[5] R. Sacco,et al. Arterial Stiffness and Wave Reflection: Sex Differences and Relationship With Left Ventricular Diastolic Function , 2012, Hypertension.
[6] A. Kaya,et al. Impact of Body Mass Index on Left Ventricular Diastolic Dysfunction , 2012, Echocardiography.
[7] J. McMurray,et al. Gender and survival in patients with heart failure: interactions with diabetes and aetiology. Results from the MAGGIC individual patient meta‐analysis † , 2012, European journal of heart failure.
[8] P. Macfarlane,et al. Subclinical thyroid dysfunction and the risk of heart failure in older persons at high cardiovascular risk. , 2012, The Journal of clinical endocrinology and metabolism.
[9] L. A. Bonet,et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2012, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.
[10] R. Jurcuț,et al. A personalized medicine target: heart failure in women , 2011, Journal of medicine and life.
[11] J. McMurray,et al. Eplerenone in patients with systolic heart failure and mild symptoms. , 2011, The New England journal of medicine.
[12] Wei-Yin Loh,et al. Classification and regression trees , 2011, WIREs Data Mining Knowl. Discov..
[13] Michael Böhm,et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study , 2010, The Lancet.
[14] Gregory Y H Lip,et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. , 2010, Chest.
[15] K. Dickstein,et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial , 2009, The Lancet.
[16] I. Piña,et al. Heart failure in women: a need for prospective data. , 2009, Journal of the American College of Cardiology.
[17] L. Leinwand,et al. Sex-based cardiac physiology. , 2009, Annual review of physiology.
[18] D. Korzick,et al. Rapid estrogen receptor-alpha activation improves ischemic tolerance in aged female rats through a novel protein kinase C epsilon-dependent mechanism. , 2009, Endocrinology.
[19] K. Swedberg,et al. Survival trends in men and women with heart failure of ischaemic and non-ischaemic origin: data for the period 1987-2003 from the Swedish Hospital Discharge Registry. , 2008, European heart journal.
[20] R. Ferrari,et al. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial , 2008, The Lancet.
[21] V. Hasselblad,et al. Cardiorenal interactions: insights from the ESCAPE trial. , 2008, Journal of the American College of Cardiology.
[22] K. Furie,et al. Heart disease and stroke statistics--2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2008, Circulation.
[23] L. Leinwand,et al. The effects of biological sex and diet on the development of heart failure. , 2007, Circulation.
[24] Peter Buhlmann,et al. BOOSTING ALGORITHMS: REGULARIZATION, PREDICTION AND MODEL FITTING , 2007, 0804.2752.
[25] P. Poole‐Wilson,et al. Tolerability and dose-related effects of nebivolol in elderly patients with heart failure: data from the Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure (SENIORS) trial. , 2007, American heart journal.
[26] S. Solomon,et al. Sex Differences in Clinical Characteristics and Prognosis in a Broad Spectrum of Patients With Heart Failure: Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) Program , 2007, Circulation.
[27] M. Walsh,et al. Low rate of sex-specific result reporting in cardiovascular trials. , 2007, Mayo Clinic proceedings.
[28] P. Austin. A comparison of classification and regression trees, logistic regression, generalized additive models, and multivariate adaptive regression splines for predicting AMI mortality , 2007 .
[29] Mark Culp,et al. ada: An R Package for Stochastic Boosting , 2006 .
[30] D. Hinkley. Annals of Statistics , 2006 .
[31] A. Tsiatis,et al. Cost-Effectiveness of Defibrillator Therapy or Amiodarone in Chronic Stable Heart Failure: Results From the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) , 2006, Circulation.
[32] G. Fonarow,et al. Gender differences in in-hospital management and outcomes in patients with decompensated heart failure: analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). , 2006, Journal of cardiac failure.
[33] A. Moss,et al. Predictive value of ventricular arrhythmia inducibility for subsequent ventricular tachycardia or ventricular fibrillation in Multicenter Automatic Defibrillator Implantation Trial (MADIT) II patients. , 2006, Journal of the American College of Cardiology.
[34] A. Owen. Cost-effectiveness of cardiac resynchronization therapy: results from the CARE-HF trial. , 2005, European heart journal.
[35] D. Kass,et al. Cost effectiveness of cardiac resynchronization therapy in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial. , 2005, Journal of the American College of Cardiology.
[36] A. Hoes,et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. , 2005, European heart journal.
[37] G. Biondi-Zoccai,et al. Reduced post-infarction myocardial apoptosis in women: a clue to their different clinical course? , 2003, Heart.
[38] J. Daubert,et al. Cost-effectiveness of cardiac resynchronization therapy: results from the CARE-HF trial. , 2006, European heart journal.
[39] M. Cavasin,et al. Gender differences in cardiac function during early remodeling after acute myocardial infarction in mice. , 2004, Life sciences.
[40] B. Yawn,et al. Trends in heart failure incidence and survival in a community-based population. , 2004, JAMA.
[41] D. Ruppert. The Elements of Statistical Learning: Data Mining, Inference, and Prediction , 2004 .
[42] W. Kannel,et al. Incidence and Epidemiology of Heart Failure , 2000, Heart Failure Reviews.
[43] R. Redberg,et al. Gender and valvular surgery. , 2004, The Journal of thoracic and cardiovascular surgery.
[44] J. López-Sendón,et al. The EPHESUS Trial: Eplerenone in Patients with Heart Failure Due to Systolic Dysfunction Complicating Acute Myocardial Infarction , 2004, Cardiovascular Drugs and Therapy.
[45] S. Lemon,et al. Classification and regression tree analysis in public health: Methodological review and comparison with logistic regression , 2003, Annals of behavioral medicine : a publication of the Society of Behavioral Medicine.
[46] S. A. Gansky,et al. Dental Data Mining: Potential Pitfalls and Practical Issues , 2003, Advances in dental research.
[47] Karl Swedberg,et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial , 2003, The Lancet.
[48] M. Pfeffer,et al. VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in context , 2003, European journal of heart failure.
[49] Jeffrey L. Anderson,et al. Failure of benefit and early hazard of bucindolol for Class IV heart failure. , 2003, Journal of cardiac failure.
[50] P. Poole‐Wilson,et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial , 2003, The Lancet.
[51] N. Freemantle,et al. The EuroHeart Failure Survey programme - a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment , 2003 .
[52] N Freemantle,et al. The EuroHeart Failure survey programme-- a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. , 2003, European heart journal.
[53] D. DeMets,et al. Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart Failure: Results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study , 2002, Circulation.
[54] M. Lauer,et al. The prognostic value of estimated creatinine clearance alongside functional capacity in ambulatory patients with chronic congestive heart failure. , 2002, Journal of the American College of Cardiology.
[55] J. Tu,et al. Prognosis and Determinants of Survival in Patients Newly Hospitalized for Heart Failure: A Population-Based Study , 2002 .
[56] Heinrich Taegtmeyer,et al. Obesity and the risk of heart failure. , 2002, The New England journal of medicine.
[57] A. Jacobs,et al. Absence of gender differences in clinical outcomes in patients with cardiogenic shock complicating acute myocardial infarction. A report from the SHOCK Trial Registry. , 2001, Journal of the American College of Cardiology.
[58] A. Tedgui,et al. Age and gender effects on cardiomyocyte apoptosis in the normal human heart. , 2001, The journals of gerontology. Series A, Biological sciences and medical sciences.
[59] E. Levin. highlighted topics Genome and Hormones: Gender Differences in Physiology Invited Review: Cell localization, physiology, and nongenomic actions of estrogen receptors , 2001 .
[60] Jennifer Y. Liu,et al. Glycemic Control and Heart Failure Among Adult Patients With Diabetes , 2001, Circulation.
[61] A. Clerk,et al. Akt like a woman: gender differences in susceptibility to cardiovascular disease. , 2001, Circulation research.
[62] Mark A Sussman,et al. Myocardial Akt Activation and Gender: Increased Nuclear Activity in Females Versus Males , 2001, Circulation research.
[63] K. Dickstein,et al. Comparison of baseline data, initial course, and management: losartan versus captopril following acute myocardial infarction (The OPTIMAAL Trial). OPTIMAAL Trial Steering Committee and Investigators. Optimal Trial in Myocardial Infarction with the Angiotensin II Antagonist Losartan. , 2001, The American journal of cardiology.
[64] T. Simon,et al. Sex Differences in the Prognosis of Congestive Heart Failure: Results From the Cardiac Insufficiency Bisoprolol Study (CIBIS II) , 2001, Circulation.
[65] Trevor Hastie,et al. The Elements of Statistical Learning , 2001 .
[66] J. Cohn,et al. Baseline demographics of the Valsartan Heart Failure Trial , 2000, European journal of heart failure.
[67] D. R. Gross,et al. Effect of estrogen on global myocardial ischemia-reperfusion injury in female rats. , 2000, American journal of physiology. Heart and circulatory physiology.
[68] B. Pitt,et al. The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure , 2000 .
[69] Bertram Pitt,et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II , 2000, The Lancet.
[70] B. Vanhaesebroeck,et al. The PI3K-PDK1 connection: more than just a road to PKB. , 2000, The Biochemical journal.
[71] P A Poole-Wilson,et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. , 1999, Circulation.
[72] C. di Loreto,et al. Myocyte death in the failing human heart is gender dependent. , 1999, Circulation research.
[73] M. Kostkiewicz,et al. Left ventricular geometry and function in patients with aortic stenosis: gender differences. , 1999, International journal of cardiology.
[74] B. Pitt,et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.
[75] P. Douglas,et al. Gender differences in molecular remodeling in pressure overload hypertrophy. , 1999, Journal of the American College of Cardiology.
[76] Fach,et al. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF) , 1999, The Lancet.
[77] G. Koch,et al. Gender differences in survival in advanced heart failure. Insights from the FIRST study. , 1999, Circulation.
[78] M. Greenberg,et al. Akt Promotes Cell Survival by Phosphorylating and Inhibiting a Forkhead Transcription Factor , 1999, Cell.
[79] CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial , 1999, The Lancet.
[80] John Bell,et al. Tree-based methods , 1999 .
[81] W Sauerbrei,et al. Differentiation of Benign and Malignant Breast Tumors by Logistic Regression and a Classification Tree using Doppler flow signals , 1998, Methods of Information in Medicine.
[82] Ping H Wang,et al. Insulin-like growth factor I modulates induction of apoptotic signaling in H9C2 cardiac muscle cells , 1998 .
[83] D A Bloch,et al. Recursive partitioning for the identification of disease risk subgroups: a case-control study of subarachnoid hemorrhage. , 1998, Journal of clinical epidemiology.
[84] R. Karas,et al. Cardiac myocytes and fibroblasts contain functional estrogen receptors 1 , 1997, FEBS letters.
[85] A. Koller,et al. Gender difference in myogenic tone of rat arterioles is due to estrogen-induced, enhanced release of NO. , 1997, The American journal of physiology.
[86] Elizabeth Yang,et al. Serine Phosphorylation of Death Agonist BAD in Response to Survival Factor Results in Binding to 14-3-3 Not BCL-XL , 1996, Cell.
[87] P. Petrusz,et al. Estradiol stimulates tyrosine phosphorylation of the insulin-like growth factor-1 receptor and insulin receptor substrate-1 in the uterus. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[88] Yoav Freund,et al. Experiments with a New Boosting Algorithm , 1996, ICML.
[89] P. Anversa,et al. Gender differences and aging: effects on the human heart. , 1995, Journal of the American College of Cardiology.
[90] Daniel L. McGee,et al. Left ventricular hypertrophy has a greater impact on survival in women than in men. , 1995, Circulation.
[91] D. Levy,et al. Sex differences in cardiac adaptation to isolated systolic hypertension. , 1993, The American journal of cardiology.
[92] S. Yusuf,et al. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. , 1992, The New England journal of medicine.
[93] D. Herrington,et al. Short-term administration of estrogen and vascular responses of atherosclerotic coronary arteries. , 1992, Journal of the American College of Cardiology.
[94] Salim Yusuf,et al. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.
[95] K. Swedberg,et al. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). , 1988, The American journal of cardiology.
[96] J. Scheuer,et al. Effects of gonadectomy and hormonal replacement on rat hearts. , 1987, Circulation research.
[97] C. Mackenzie,et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.
[98] M. Pfeffer,et al. Favorable effects of therapy on cardiac performance in spontaneously hypertensive rats. , 1982, The American journal of physiology.